Companies › Vyriad
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VV1 Oncolytic virus expressing interferon-beta | – | Phase 2 | Melanoma | Dec 2026 |
| VV169 In vivo BCMA-CAR T cell therapy (T-cell targeted lentiviral vector expressing BCMA-directe | TNFRSF17 | Phase 1 | Multiple Myeloma Refractory | Aug 2027 |
| VSV-IFNβ-NIS Oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and sodium io | – | Phase 1 | Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03647163 | VSV-IFNβ-NIS | Phase 1 | Solid Tumor | Oncology | Jul 2025 |
| NCT04291105 | VV1 | Phase 2 | Melanoma | Oncology | Dec 2026 |
| NCT07802717 | VV169 | Phase 1 | Multiple Myeloma Refractory | Oncology | Aug 2027 |
Vividion Therapeutics Tesaro HRYZ Biotech ImmVira Pharma Guangzhou Virotech Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.